1461098344-26eaa7e6-f6d6-4735-9740-84101cbc5253

1. A method for treating sexual dysfunction in a female individual, comprising administering to the vagina, vulvar area or urethra of the individual a pharmaceutical formulation that comprises an effective amount of a vasoactive agent selected from the group consisting of naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, calcium channel blockers, phosphodiesterase inhibitors, nitrates, -receptor blocking agents, ergotamine drugs, antihypertensive agents, pharmacologically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes of any of the foregoing, and combinations thereof.
2. The method of claim 1, wherein the pharmaceutical formulation further includes a pharmaceutically acceptable carrier suited to vaginal, vulvar or transurethral drug administration.
3. The method of claim 1, wherein the vasoactive agent is a naturally occurring prostaglandin or a hydrolyzable lower alkyl ester thereof.
4. The method of claim 3, wherein the naturally occurring prostaglandin is selected from the group consisting of PGE0, PGE1, PGA1, PGB1, PGF1, 19-hydroxy-PGA1, 19-hydroxy-PGB1, PGE2, PGA2, PGB2, 19-hydroxy-PGA2, 19-hydroxy-PGB2, PGE3, PGF3, PGI2, and combinations thereof.
5. The method of claim 4, wherein the naturally occurring prostaglandin is PGE0.
6. The method of claim 4, wherein the naturally occurring prostaglandin is PGE1.
7. The method of claim 4, wherein the naturally occurring prostaglandin is PGE2.
8. The method of claim 1, wherein the vasoactive agent is a synthetic prostaglandin derivative or a hydrolyzable lower alkyl ester thereof.
9. The method of claim 8, wherein the synthetic prostaglandin derivative is selected from the group consisting of carboprost tromethamine, dinoprost tromethamine, gemeprost, metenoprost, sulprostone and tiaprost.
10. The method of claim 1, wherein the vasoactive agent is an endothelial-derived relaxation factor.
11. The method of claim 10, wherein the endothelial-derived relaxation factor is a nitric oxide releasing agent.
12. The method of claim 11, wherein the nitric oxide releasing agent is selected from the group consisting of nitroglycerin, sodium nitroprusside, NONOates, molsidomine, linsidomine (SIN-1) and S-nitrosothiols.
13. The method of claim 1, wherein the vasodilating agent is a vasoactive intestinal polypeptide agonist.
14. The method of claim 1, wherein the vasoactive agent is a smooth muscle relaxant.
15. The method of claim 1, wherein the vasoactive agent is a leukotriene inhibitor.
16. The method of claim 1, wherein the vasoactive agent is a calcium channel blocker.
17. The method of claim 1, wherein the vasoactive agent is a phosphodiesterase inhibitor.
18. The method of claim 17, wherein the phosphodiesterase inhibitor is selected from the group consisting of Type III phosphodiesterase inhibitors, Type IV phosphodiesterase inhibitors and Type V phosphodiesterase inhibitors.
19. The method of claim 18, wherein the phosphodiesterase inhibitor is a Type V phosphodiesterase inhibitor.
20. The method of claim 1, wherein the vasoactive agent is a nitrate.
21. The method of claim 20, wherein the vasoactive agent is selected from the group consisting of nitroglycerin, isosorbide dinitrate and erythrityl tetranitrate.
22. The method of claim 1, wherein the vasoactive agent is an -receptor blocking agent.
23. The method of claim 22, wherein the vasoactive agent is selected from the group consisting of prazosin, doxazosin, terazosin, tolazoline, phentolamine, phenoxyberzamine, alfuzosin, tamsulosin, indornmin, trimazosin, dibenamine and combinations thereof.
24. The method of claim 1, wherein the pharmaceutical formulation further includes a steroid.
25. The method of claim 24, wherein the steroid is selected from the group consisting of progestins, estrogens and mixtures thereof.
26. The method of claim 1, wherein the pharmaceutical formulation further includes a compound selected from the group consisting of steroid agonists, partial agonists and antagonists.
27. The method of claim 26, wherein the compound is selected from the group consisting of steroid agonists and partial agonists.
28. The method of claim 26, wherein the compound is selected from the group consisting of tamoxifen, cenchroman, clomiphene, droloxifene, raloxifene and pharmaceutically acceptable salts thereof.
29. The method of claim 1, wherein the pharmaceutical formulation additionally includes a detergent in an amount effective to increase solubility of the vasoactive agent in the vehicle and bioavailability of the agent following administration.
30. The method of claim 3, wherein the pharmaceutical formulation further includes an effective inhibiting amount of a compound effective to inhibit prostaglandin-degrading enzymes.
31. The method of claim 8, wherein the pharmaceutical formulation further includes an effective inhibiting amount of a compound effective to inhibit prostaglandin-degrading enzymes.
32. The method of claim 1, wherein the pharmaceutical formulation is contained within a delivery system selected to provide a predetermined agent release profile.
33. The method of claim 32, wherein the agent release profile is pulsatile.
34. The method of claim 32, wherein the agent release profile is continuous.
35. The method of claim 32, wherein the agent release profile is cyclical.
36. The method of claim 32, wherein the agent release profile is diurnal.
37. The method of claim 1, wherein the pharmaceutical formulation is administered vaginally.
38. The method of claim 37, wherein the pharmaceutical formulation is in the form of an ointment, cream, gel, solid, solution, suspension, foam or liposomal composition.
39. The method of claim 37, wherein the pharmaceutical formulation is contained within a vaginal ring, tampon, suppository, sponge, pillow, puff, or osmotic pump system.
40. The method of claim 1, wherein the pharmaceutical formulation is administered to the vulvar area.
41. The method of claim 1, wherein the pharmaceutical formulation is administered transurethrally.
42. The method of claim 37, wherein the method further comprises co-administering an androgenic agent to the vulvar area of the individual in combination with vaginal administration of the vasoactive agent.
43. The method of claim 42, wherein the androgenic agent is testosterone or a testosterone ester.
44. A method for preventing the occurrence of a yeast infection in a female individual, comprising vaginally administering to such individual a pharmaceutical formulation that comprises a vasoactive agent selected from the group consisting of naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, calcium channel blockers, phosphodiesterase inhibitors, nitrates, -receptor blocking agents, ergotamine drugs, antihypertensive agents, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes of any of the foregoing, and combinations thereof, in combination with a pharmaceutically acceptable vehicle.
45. A method for improving vaginal muscle tone and tissue health in a female individual, comprising vaginally administering to such individual a pharmaceutical formulation that comprises a vasoactive agent selected from the group consisting of naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, calcium channel blockers, phosphodiesterase inhibitors, nitrates, -receptor blocking agents, ergotamine drugs, antihypertensive agents, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes of any of the foregoing, and combinations thereof, in combination with a pharmacologically acceptable vehicle.
46. A method for enhancing vaginal lubrication in a female individual, comprising vaginally administering to such individual a pharmaceutical formulation that comprises a vasoactive agent selected from the group consisting of naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, calcium channel phosphodiesterase blockers, phosphodiesterase inhibitors, nitrates, -receptor blocking agents, ergotamine drugs, antihypertensive agents, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes of any of the foregoing, and combinations thereof, in combination with a pharmacologically acceptable vehicle.
47. A method for minimizing excess collagen deposition in a female individual, comprising vaginally administering to such individual a pharmaceutical formulation that comprises a vasoactive agent selected from the group consisting of naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, calcium channel blockers, phosphodiesterase inhibitors, nitrates -receptor blocking agents, ergotamine drugs, antihypertensive agents, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes of any of the foregoing, and combinations thereof in combination with a pharmacologically acceptable vehicle.
48. A pharmaceutical formulation for treating sexual dysfunction in a female individual, comprising an amount of a vasoactive agent effective to treat female sexual dysfunction, wherein the vasoactive agent is selected from the group consisting of naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, calcium channel blockers, phosphodiesterase inhibitors, nitrates -receptor blocking agents, ergotamine drugs, antihypertensive agents, pharmaceutically acceptable salts, esters, analogs, derivatives, prodrugs and inclusion complexes of any of the foregoing, and combinations thereof, in combination with a vehicle suited to vaginal, vulvar or transurethral drug administration.
49. The pharmaceutical formulation of claim 48, wherein the vasoactive agent is a naturally occurring prostaglandin or a hydrolyzable lower alkyl ester thereof.
50. The pharmaceutical formulation of claim 49, wherein the naturally occurring prostaglandin is selected from the group consisting of PGE0, PGE1, PGA1, PGB1, PGF1, 19-hydroxy-PGA1, 19-hydroxy-PGB1, PGE2, PGA2, PGB2, 19-hydroxy-PGA2, 19-hydroxy-PGB2, PGE3, PGF3 and PGI2, and combinations thereof.
51. The pharmaceutical formulation of claim 48, wherein the vasoactive agent is a synthetic prostaglandin derivative or a hydrolyzable lower alkyl ester thereof.
52. The pharmaceutical formulation of claim 51, wherein the synthetic prostaglandin derivative is selected from the group consisting of carboprost tromethamine, dinoprost tromethamine, dinoprostone, gemeprost, metenoprost, sulprostone and tiaprost.
53. A drug delivery device for administering a pharmaceutical formulation directly to the clitoral area of a female individual comprising an elongate patch having an upper region and a lower region, wherein the upper region includes a drug reservoir and a clitoral applicator.
54. The device of claim 53, wherein the clitoral applicator comprises an upwardly extending protuberance disposed over the drug reservoir and adapted to fit over the clitoral area of the individual.
55. The device of claim 54, wherein the drug reservoir is defined by a permeable membrane encircling the base of the protuberance and is adapted to contain a pharmaceutical formulation.
56. The device of claim 55, wherein the pharmaceutical formulation is effective to treat sexual dysfunction in a female individual, and comprises an effective amount of a vasoactive agent.
57. The device of claim 53, wherein the upper and lower regions of the patch are shaped to be coextensive with the upper and lower portions of the genitalia.
58. The device of claim 53, wherein the protuberance is provided with a suction tip for positioning the applicator over the clitoris.
59. A method for using the device of claim 54, comprising the steps of:
(a) positioning the protuberance of the clitoral applicator to extend into the clitoral hood; and
(b) maintaining the device in place for sufficient time to administer a therapeutically effective amount of the pharmaceutical formulation contained in the drug reservoir to the individual.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A print control apparatus which transmits print data to a printing apparatus according to a print instruction for a logical printer, comprising:
a logical printer information management unit configured to manage logical printer information predefined for each of logical printers, the logical printer information including a logical printer name of a corresponding one of the logical printers and an indicator indicating whether the corresponding one of the logical printers is a portless printer that is not associated with any printing apparatus;
a printing apparatus search unit; and
a print data transmitting unit configured to determine whether the logical printer specified in the print instruction is a portless printer based on the indicator in the logical printer information, wherein
if the logical printer specified in the print instruction is a portless printer, the print data transmitting unit is configured to request the printing apparatus search unit to search for printing apparatuses connected to a network and to transmit the print data to a network address of one of the printing apparatuses found by the printing apparatus search unit.
2. The print control apparatus as claimed in claim 1, further comprising:
a printing apparatus list display unit which displays a list of printing apparatuses found by the printing apparatus search unit, wherein the print data transmitting unit transmits the print data to a network address of a printing apparatus selected from the printing apparatus list.
3. The print control apparatus as claimed in claim 1, wherein the network address to which the print data are transmitted by the print data transmitting unit is registered in the logical printer information as the network address of the logical printer specified in the print instruction.
4. The print control apparatus as claimed in claim 1, wherein
the printing apparatus search unit obtains status information of the printing apparatuses connected to the network and determines availability of the printing apparatuses based on the status information, and
the print data transmitting unit transmits the print data to one of the available printing apparatuses if the network address corresponding to the logical printer specified in the print instruction is not registered in the logical printer information.
5. The print control apparatus as claimed in claim 1, wherein the printing apparatus search unit searches for another printing apparatus if the printing apparatus corresponding to the network address registered in the logical printer information of the logical printer specified in the print instruction is not available.
6. The print control apparatus as claimed in claim 1, wherein the printing apparatus search unit searches for printing apparatuses in a same network segment as that of the print control apparatus.
7. A print control system which transmits print data to a printing apparatus according to a print instruction for a logical printer, comprising:
a logical printer information management unit configured to manage logical printer information predefined for each of logical printers, the logical printer information including a logical printer name of a corresponding one of the logical printers and an indicator indicating whether the corresponding one of the logical printers is a portless printer that is not associated with any printing apparatus;
a printing apparatus search unit; and
a print data transmitting unit configured to determine whether the logical printer specified in the print instruction is a portless printer based on the indicator in the logical printer information, wherein
if the logical printer specified in the print instruction is a portless printer, the print data transmitting unit is configured to request the printing apparatus search unit to search for printing apparatuses connected to a network and to transmit the print data to a network address of one of the printing apparatuses found by the printing apparatus search unit.
8. A print control method which transmits print data to a printing apparatus according to a print instruction for a logical printer, comprising:
managing logical printer information predefined for each of logical printers, the logical printer information including a logical printer name of a corresponding one of the logical printers and an indicator indicating whether the corresponding one of the logical printers is a portless printer that is not associated with any printing apparatus; and
determining whether the logical printer specified in the print instruction is a portless printer based on the indicator in the logical printer information; and
searching for printing apparatuses connected to the network and transmitting the print data to a network address of one of the printing apparatuses found in the printing apparatus search if the logical printer specified in the print instruction is a portless printer.
9. A recording medium having a program embodied therein for causing a computer to transmit print data to a printing apparatus according to a print instruction for a logical printer, said program comprising:
a logical printer information management code unit configured to manage logical printer information predefined for each of logical printers, the logical printer information including a logical printer name of a corresponding one of the logical printers and an indicator indicating whether the corresponding one of the logical printers is a portless printer that is not associated with any printing apparatus;
a printing apparatus search code unit; and
a print data transmitting code unit configured to determine whether the logical printer specified in the print instruction is a portless printer based on the indicator in the logical printer information, wherein
if the logical printer specified in the print instruction is a portless printer, the print data transmitting code unit is configured to request the printing apparatus search code unit to search for printing apparatuses connected to a network and to transmit the print data to a network address of one of the printing apparatuses found by the printing apparatus search code unit.
10. The recording medium as claimed in claim 9, said program further comprising:
a printing apparatus list display code unit which displays a list of printing apparatuses found by the printing apparatus search code unit, wherein the print data transmitting code unit transmits the print data to a network address of a printing apparatus selected from the printing apparatus list.
11. The recording medium as claimed in claim 9, said program further comprising:
an address registration code unit which registers the network address, to which the print data are transmitted by the print data transmitting step, in the logical printer information as the network address of the logical printer specified in the print instruction.
12. The recording medium as claimed in claim 9, wherein
the printing apparatus search code unit of said program obtains status information of the printing apparatuses connected to the network and determines availability of the printing apparatuses based on the status information, and
the print data transmitting code unit of said program transmits the print data to one of the available printing apparatuses if the network address corresponding to the logical printer specified in the print instruction is not registered in the logical printer information.
13. The recording medium as claimed in claim 9, wherein the printing apparatus search code unit of said program searches for another printing apparatus if the printing apparatus corresponding to the network address registered in the logical printer information of the logical printer specified in the print instruction is not available.
14. The recording medium as claimed in claim 9, wherein the printing apparatus search code unit of said program searches for printing apparatuses in a same network segment as that of said program.